Cryoport, Inc. (CYRX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX). Investors who purchased Cryoport securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Cryoport has violated federal securities laws.
Investigation Details:
On July 12, 2023, Cryoport revealed its preliminary second-quarter financial results, and said its second-quarter 2023 total revenue “is expected to be in the range of $56.5 to $57.5 million, representing a decrease of 11%, at the midpoint, compared to the second quarter of 2022.” Cryoport attributed the shortfall to “a global slowdown in capital equipment investment” and “a number of clinical trial start delays and several key customers falling short of their forecasts for the revenue ramp of certain cell and gene therapies.” Following this news, Cryoport stock dropped $4.80 per share, or 24.7%, to close at $16.60 on July 13, 2023.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Cryoport securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.